ArticleBMC microbiology2026
Genetic variants of AcrAB and OqxAB and the impact of efflux pump inhibition on ciprofloxacin and amikacin resistance in clinical isolates of Klebsiella pneumoniae from Lima, Peru.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKlebsiella pneumoniae is a World Health Organization priority pathogen because of its rapidly accumulating resistance to multiple drug classes. Over-expression of the AcrAB and OqxAB Resistance-Nodulation-Division (RND) efflux pumps is a key mechanism, yet genomic data on these systems in Peruvian strains are scarce.
methodsSixteen non-duplicate K. pneumoniae isolates obtained from hospitalised patients in Lima (2019–2020) were tested for ciprofloxacin and amikacin susceptibility by broth microdilution, with and without the efflux-pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP) and phenylalanine-arginine β-naphthylamide (PAβN). AcrA, AcrB, OqxA and OqxB were detected by PCR, and the resulting amplicons were sequenced on the Oxford Nanopore platform. Reads were analysed with Epi2me (Amplicon workflow); single nucleotide polymorphisms (SNPs) were identified by aligning to reference sequences in MEGA, and all sequences were deposited in GenBank.
resultsResistance to ciprofloxacin and amikacin was evaluated in all isolates; 93.8% were resistant to ciprofloxacin and 18.8% to amikacin. PAβN produced a ≥ 4-fold MIC reduction in 18.8% (ciprofloxacin) and 100% (amikacin) of resistant strains; CCCP yielded a ≥ 3-fold decrease in 75% of ciprofloxacin resistant isolates. AcrB and AcrA were detected in 56.3% and 43.8% of isolates, while OqxB and OqxA occurred in 25.0% and 31.3%, respectively. Nanopore sequencing con-firmed gene identity and revealed 12 SNPs detected, OqxB c.56 G > T (V19F) and c.356 C > A (P119H), which may modulate efflux efficiency.
conclusionEfflux-mediated resistance to ciprofloxacin and amikacin in clinical isolates of K. pneumoniae is underpinned by genetic variants in the AcrAB and OqxAB pumps. The incorporation of long-read amplicon sequencing exposes SNP-level variation missed by conventional PCR studies and underscores the value of routine genomic surveillance. The MIC reversals observed with PAβN and CCCP against these two antibiotics highlight efflux pump inhibition as a promising complementary strategy against resistant K. pneumoniae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.